Paola Grandi, PhD Birth Date - American Society of Gene & Cell ...

CURRICULUM VITAEName: Paola Grandi, PhD Birth Date: February 20, 1973Home Address: 5220 5 th ave Birth Place: Bologna, ItalyPittsburgh, PA 15232 Citizenship: ItalianBusiness Address: University of Pittsburgh Business Phone: 1(412)648-9461Department of Neurological Surgery Business Fax: 1(412)624-8997UPMC Presbyterian, Suite B-400E-Mail Address: pag24@pitt.edu200 Lothrop StreetPittsburgh, PA 15213EDUCATION and TRAININGUndergraduate1992-1996 University of Ferrara B.S. BiologyFerrara, ItalyGraduate1996-1997 University of Ferrara M.Sc. GeneticsFerrara, Italy1997-2001 University of Ferrara Ph.D. BiochemistryFerrara, ItalyAPPOINTMENTS and POSITIONSAcademic04/2005-present Assistant Professor, Department of Neurological Surgery, University of Pittsburgh12/2004-03/2005 Researcher Associate, Department of Neurological Surgery, University of Pittsburgh01/2002-11/2004 Post-doc (Neurology) Molecular Neurogenetics Unit, Massachusetts General Hospital, HarvardMedical School, Massachusetts, USA05/2001-12/2001 Fellow Research (Neurology) Molecular Neurogenetics Unit, Massachusetts General Hospital,Harvard Medical School, Massachusetts, USA12/1997-04/2001 Research project working on amplicon vectors as a novel approach to HIV-1 vaccinedevelopment, Department of Experimental and Diagnostic Medicine (Section of Microbiology),University of Ferrara, Italy01/1997-12/1997 M. Sc. Training in Genetic, at the Department of Experimental and Diagnostic Medicine (Sectionof Genetics), University of Ferrara, Italy03/1994-12/1996 Undergraduate student at the Department of Experimental and Diagnostic Medicine (Section ofMicrobiology), University of Ferrara, Italy, B.Sc. training in VirologyYear2001-present2003-present2006-present2009-PresentMEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIESOrganizationAmerican Society of Gene TherapyAmerican Association of Cancer ResearchSociety for NeuroimmunologyInternational Society for Stem cell Research

HONORS1996 B.Sc. in Biology: degree with 110/110 cum laude from University of Ferrara;1997 M.Sc. in Genetic: degree with distinction;2001 Ph.D degree with optimum from University of Ferrara;2001 Only fellowship for US study from University of Ferrara.2005 travel award for the best oral presentation at the International Herpesvirus Workshop, Turku, Finland.2012 Scientist of the month (march) from American Society for Gene and Cell therapy.Under revision:PUBLICATIONSLucia Mazzacurati, Marco Marzulli, Bonnie Reinhard, Yoshitaka Miagawa, Nino Chiocca, Joseph Glorioso, PaolaGrandimir124-controlled HSV1 based oncolytic vecto for treatment of Glioblastoma Multiforme (Submitted cancer research)Publications in Scientific Journals:1. Uchida H, Chan J, Shrivastava I, Reinhart B, Grandi P, Glorioso JC, Cohen JB. Novel mutations in gB and gHcircumvent the requirement of known gD Receptors in herpes Simplex Virus 1 Entry and cell-to-cell spread. JVirol. 2013 Feb;87(3):1430-42. doi: 10.1128/JVI.02804-12. Epub 2012 Nov 14.2. Hiroaki Uchida, Marco Marzulli, William F. Goins, Janet Chan, Chang-Sook Hong, Lucia Mazzacurati, Ji Y.Yoo, Amy Haseley, Hiroshi Nakashima, Kenji Nakano, Hyunjung Baek, Heechung Kwon, Izumi Kumagai,Masahide Kuroki, Balveen Kaur, E. Antonio Chiocca, Paola Grandi, Justus B. Cohen, and Joseph C. Glorioso.Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-RetargetedOncolytic Herpes Simplex Virus. Mol. Therapy 2012, Oct 163. Bonnie Reinhart, Lucia Mazzacurati, Adriana Forero, Chang-Sook Hong, Junichi Eguchi, Hideho Okada, WendyFellow, Ajay Niranjan, Justus Cohen, J. C. Glorioso and Paola Grandi. Inhibition of Indoleamine-2,3-Dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Advances in Virology. 2012;2012:8154654. Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Gene Ther. 2010Sep;17(9):655-63. Epub 2010 May 28.5. Uchida H, Chan J, Goins WF, Grandi P, Kumagai I. Cohen JB, and Glorioso, JC. A double mutation inglycoprotein B compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. JVirol. Dec; 84(23): 12200-9, 2010.6. Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, Glorioso JC, Grandi P. Ectopic matrixmetalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther.Oct; 17(10): 1200-5, 2010.7. Frampton AR Jr, Uchida H, von Einem J, Goins WF, Grandi P, Cohen JB, Osterrieder N, Glorioso JC. Equineherpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. VetMicrobiol. 2010 Feb 24;141(1-2):12-21. Epub 2009 Aug 8.8. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSVvectors for glioblastoma therapy. Expert Rev Neurother. 2009 Apr;9(4):505-179. Uchida H, Shah WA, Ozuer A, Frampton AR Jr, Goins WF, Grandi P, Cohen JB, Glorioso JC. Generation ofherpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEMexpressingcells and identification of mutations that rescue nectin-1 recognition. J Virol. 2009 Apr;83(7):2951-61.10. H. Li, D. Krisky, P. Grandi, R. Baskaran, J. C. Glorioso . HSV-1 ICP0 activates Chk2 to induce G2/M arrest andto enhance virus growth. Virology. 2008 May 25;375(1):13-232

11. Bozac, Berto E., VasquezF., Grandi P., Caputo A., Mnaservigi R., Ensoli B., Marconi P. Expression of HumanImmunodeficiency Virus Type 1 tat from a replication-deficient herpes simplex vector induces antigen-specific Tcell responses. Vaccine. 2006 Nov 30;24(49-50):7148-58. Epub 2006 Jul 12.12. Grandi P., Fernadez J., Szemntirmai O., Carter R., Breakefield X., Sena- Esteves M. Targeting HSV-1 virions forspecific binding to Epidermal Growth Factor Receptro-vIII on Tumor cells. (2006) Mol. Therapy. 13: 16813. Trevor McKee 1 , Paola Grandi 1 , Wilson Mok, George Alexandrakis, Numpon Insin, John P. Zimmer, Moungi G.Bawendi, Yves Boucher Xandra O. Breakefield and Rakesh K. Jain. Degradation of fibrillar collagen within solidtumors improves the efficacy of oncolytic viral therapy (2006). Cancer Research 66 (5): 2509-13 1 authorscontributed equally14. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1virions engineered for specific binding to cell surface receptor (2004) Mol. Therapy, 9: 419-27.15. Grandi P., Spear M., Breakefield X., Wang S. Targeting HSV-1 vectors (2004). Methods, 33:179-186.16. Spear M., Schuback D., Miyata K., Grandi P., Sun F., Yoo L., Nguyen A., Brandt C.R., Breakefield X. HSV-1amplicon peptide display vector (2003). Journal of Virological Methods; 107: 71-79.17. Garrafa E., Argnani R, Marconi P., Grandi P., Zerbinati A., Bozac A., Berto E., Gardo G., Fugagnoli S.,Catalano C., Grossi M.P., Balboni P.G., Manservigi R. Virus erpetici come vettori vaccinali. (2003). L’IgieneModerna 119: 251-266.18. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1amplicon vector engineered for specific binding to pseudo His-tag receptor. (2002) Mol. Ther. 5: 320.19. Caselli E., Grandi P., Argnani R., Balboni P.G., Braga F. and Manservigi R. Mice genetic immunization withplasmid DNA encoding a secreted form of HSV-1 gB1 induce a protective immune response against HSV-1infection and establishment of latency (2001). Intervirology; 44: 1-7.20. Monini, P., de Lellis L, Rimesi, P., GRANDI P., Franco M, Leone L, Rosso R, Rossi T., Aiuti F, Ledi G. L.,Ensoli, B., Cassai, E (1997). Presence of HHV-8 DNA in semen of inmmunocompetent HIV-negative individualsfrom different geographical areas in Italy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMESAND HUMAN RETROVIROLOGY, ISSN: 1077-9450Book Chapters:1. Grandi, P., Bein, K., Hadjipanayis, C. G., Wolfe, D., Breakefield, X. O. Glorioso, J.C. “Application of HSV-1Vectors to the Treatment of Cancer”. "Viral Therapy of Cancer"Book, edited by Kevin Harrington, HardevPandha and Richard Vile (April 2008).2. Kohn, D.B., Carter, B., Glorioso, J.C. , Grandi P. “Gene Therapy and Viruses”. Clinical Virology. Chapter 20.2008PROFESSIONAL ACTIVITIES2005-2010 Assistant Editor for the Nature Group Journal, Gene Therapy2010-present ASGCT webtaskforce2011 ASGCT Cancer Gene & Cell Therapy Commette2012 Founder of ACAREF: Allied Community Ataxia Research FoundationTEACHING EXPERIENCE2008-present Integrated Cases Studies (ICS) course – Medical Students2010– present Experimental Virology - MVM PhD program2010 Medical Microbiology (MS1)ACTIVERESEARCH3

2P01 NS40923-06 (Pollack) 02/26/08-02/28/13 50%NIH/NINDSNovel Strategies for Brain Tumor TherapyProject 3 (PI: Glorioso and Grandi) Novel Oncolytic HSV Vectors and Enhanced Anti-Tumor ActivityThe unifying hypothesis of this program project grant is that novel therapeutic approaches that take into accountthe unique features of CNS tumors will have utility for preventing tumor growth and inducing tumor regression.PENDINGNIH: 1R01 1A175052-01PI: Grandi PaolaEnhanced GBM Therapy Using a New Class of HSV Oncolytic VectorNIH P01 (Chiocca) Co-PI: GrandiProject 1: Circumventing Barriers to Effective Oncolytic Virotherapy of Neural TumorsPE-2011-02348974 Italian grant for researcher abroadRe-programming Human Cord and Peripheral Blood Cells to PluripotencyThis grantwill be reviewed at the NIHCOMPLETED5P01 NS40923-03 (PI : Pollack, co-PI Grandi) 07/01/02-05/31/07Program Project GrantProject 4 Vector Delivery to Modify the Brain Tumor Novel Strategies for Brain Tumor Therapy and itsMicroenvironmentThe overall goal of this program project is to further develop HSV non –replicative vectors for treatment GBM incombination with GV and gamma-kmifeD2007-0621 (Grandi) 10/15/07-10/15/08The Copeland foundationNovel HSV Oncolytic Vectors with Enhanced Efficacy for Treatment of Glioblastoma1R01 CA 119298-01 (Glorioso and Grandi) 12/01/05-11/30/10 10%NIH/NCI $333.213Glioma Gene Therapy Using Targeted OncolyticHSV Vectors4

In this proposal, experiments are outlined to explore methods to enhance the potency of HSV oncolytic vectorsthrough improved vector distribution within the tumor mass, the testing of additional mutant vector backboneswhose performance may be improved by enhanced and more specific intr-tumoral replication and through the useof additional transgenes that may be more effective in destruction of the tumor mass including locally infiltratingtumor cells into normal brain tissue. Throughout this investigation vector performance and tumor killing will beevaluated in combination with radiosurgery. We will use the performance of G207 as a benchmark with which tocompare any vector improvements.Presentations and Invited LecturesMonini P., de Lellis L., Lenette E. T., Rimessi P., GRANDI P., Franco M., Leone P., Lodi G.L., Rossi T., Levy J. A.,Rezza G., Cassai E., Ensoli B (1997). PCR detection of HHV-8 DNA in sperm and HHV-8 antibodies detection inimmunocompetent individuals from Italy. In: Acts of “Second International Conference on Human Herpesviruses 6, 7 and8Monini P., de Lellis L., Rimessi P., GRANDI P., Franco M., Leone L., Rosso R., Rossi T., Aiuti F., Lodi G. L., Ensoli B.and Cassai E (1997). Presence of HHV-8 DNA in semen of immunocompetent HIV-negative individuals from differentgeographical areas in Italy. In: Acts of “National AIDS Malignancy Conference". Bethesda, Marylan, 28-30 April 1997Caselli E, Balboni PG, Incorvaia C, Parmeggiani F, Borsato GM, Bozzini R, GRANDI P., Grossi MP, Manservigi R.(1999). Nuovi approcci per lo sviluppo di un vaccino anti-HSV-1: applicazione ed efficacia dell'immunizzazione geneticae/o perioculare basate sulla gB1s nel coniglio. . In: CNB3 - 3° Congresso Nazionale Biotecnologie. Urbino, Italy, 1-3luglio 1999Consorzio Interuniversitario Biotecnologie, p. 78-78Secchiero P., Bozzini P., GRANDI P., Balboni P.G., Caselli E., Argnani R., Colle V., Manservigi R (1999). La proteinaVP22 del virus dell’herpes: un nuovo modello per la terapia genica anti-HIV-1. In: 3° Congresso del ConsorzioInteruniversitario delle BiotecnologieGRANDI P., Secchiero P., Balboni PG e Manservigi R (2000). La proteina VP22 del virus dell’Herpes: un nuovo modelloper la terapia genica anti HIV-1. In: 28° Congresso Nazionale Società Italiana di MicrobiologiaGrandi PVettori ampliconi e VP22: un nuovo sistema di delivery basato sul virus dell’Herpes simplex.Ferrara, Italy, 10 December 20University ofGRANDI P., Secchiero P, Balboni PG, Zerbinati A, Brewis N, O’Hare P, Manservigi R. (2001). HSV-1 VP22 as a genetherapy approach for HIV. MOLECULAR THERAPY, ISSN: 1525-0024Manservigi R., Marconi P., Argnani R., GRANDI P., Balboni P.G (2001). Amplicon Vectors as a novel approach to HIV-1 vaccine development. Acts of . In: Third National Research Program on AIDSGrandi P. HSV-1 amplicon vector engineered for specific binding to pseudo his-tag receptor. Boston, MGH NeuroscienceDept. 10 April 2002Grandi P. HSV-1 amplicon vector engineered for specific binding to pseudo his-tag receptor. Boston, Harvard MedicalSchool Neuroscience Dept. 25 October 20025

Božac A., Berto E., Garrafa E., Gardo G., Boccafogli L., Xausa M., Gavioli R., GRANDI P., Manservigi R., Marconi P.C.(2002). Replication defective HSV-1 vectors - a novel anti-tat vaccination strategy. In: 7th European Conference onExperimental AIDS Research-ECEARGRANDI P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X (2002). HSV-1amplicon vector engineered for specific binding to pseudo His-tag receptor. MOLECULAR THERAPY, ISSN: 1525-0024Bozac A., Berto E., Garrafa E., Gardo G., Xausa M., Boccafogli L., Gavioli R., GRANDI P., Manservigi R., Marconi P.(2002). Vettori erpetici non replicativi – vaccini innovativi contro tat. . In: 10th Congresso Nazionale S.I.M.M.O.CGrandi P. HSV-1 amplicon vector engineered for specific binding to pseudo his-tag receptor. Boston, Neurosurgery Dept.8 January 2003Grandi P. Sequential localization of two Herpes simplex virus tegument proteins to puntcate nuclear dots adjacent to ICP0domains. Boston, Harvard Medical School, Molecular Neurogenetics Dept. 6 June 2003GRANDI P., Samuel Wang, Deborah Schuback, Victor Krasnykh, Matthew Spear, David Curiel, Roberto Manservigi,Xandra Breakefield (2003). Amplicon Vector Engineered for Specific Binding to Pseudo His-Tag Receptor. In:International Herpesvirus Workshop 2003. Madison (USA), 26-31 luglio 2003Grandi P. Binding of HSV-1 vectors to a specific cell surface receptor. Can we image the infection process in vivo?Boston, Harvard Medical School, Molecular Neurogenetics Dept. 12 March 2004Grandi P. Oncolytic vectors:new strategies of tumor retargeting and imaging. University of Ferrara, Italy, 17 May 2004GRANDI P., Trevor McKee, Juliet L. Fernandez, Rakesh K. Jain, Xandra Breakefield (2004). New strategy to improvetumor infectibility of HSV-1 vectors in vivo. In: International Herpesvirus Workshop 2004. Reno, Nevada, USA, July2004Oehmig, Schuback D., GRANDI P., Fraefel C., Breakefield X (2004). Delivery of AAV REP proteins as VP16-REPfusion proteins in HSV-1 virions. In: International Herpesvirus Workshop 2004. Reno (Nevada-USA), July 25 - Friday,July 30GRANDI P., Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO (2004). HSV-1virions engineered for specific binding to cell surface receptors. MOLECULAR THERAPY, ISSN: 1525-0016GRANDI P. (2004). Binding of HSV-1 vectors to a specific cell surface receptor. Can we image the infection process invivo? , Invited speaker. University of Zurich, SwitzerlandGrandi P. Novel strategies for enhanced cancer therapy using HSV vectors. University of Pittsburgh, 13 December 2004GRANDI P. (2005). Binding of HSV-1 vectors to New Strategy to Improve Imaging and Retargeting of HSV-1 Vectors,Invited Speaker.American Society of Gene, Therapy, St. Louis, MOGRANDI P., McKee T, Mok W, Fernandez J, Breakefield X, Jain RK (2005). New Strategy To Improve Imaging andRetargeting of HSV-1 Vectors . MOLECULAR THERAPY, ISSN: 1525-0024GRANDI P., Trevor McKee, Juliet L. Fernandez, Rakesh K. Jain, Xandra Breakefield (2005). In vivo imaging ofcollagnease-enhanced hsv oncolytic vector destruction of solid tumors. In: International Herpesvirus Workshop 2005Turku, Finland, 30th July- 4th August6

GRANDI P. (2005). In vivo imaging of collagnease-enhanced hsv oncolytic vector destruction of solid tumors. , Best Oralpresentation award: International Herpesvirus Workshop, Turku, FinlandTrevor McKee, GRANDI P., Wilson Mok George Alexandrakis Yves Boucher, Xandra O. Breakefield, Rakesh K. Jain(2005). Degradation of fibrillar collagen in solid tumors improves the efficacy of oncolytic viral therapy. In: BMES.baltimore, September 28 - October 1, 2005GRANDI P. (2006). Novel Strategies for enhancing Cancer Therapy using HSV Oncolytic Vectors. , Invited Speaker.Xi’an Jiaotong , University Medical School, ChinaGRANDI P. (2006). Novel Strategies for enhancing Cancer Therapy using HSV Oncolytic Vectors. . In: CancerMolecular Diagnosis and Gene Therapy International Symposium, 2006. Xi'an, China, 22-23 October 2006Li H, Krisky D, GRANDI P., Baskaran R, Glorioso J (2006). HSV-1 ICP0 enhance viral growth through activation ofChk2 nad Induction of G2 arrest. In: International Herpesvirus Workshop . Seattle, 22-28 July 2006GRANDI P., Fernadez J., Szemntirmai O., Carter R., Breakefield X., Sena- Esteves M (2006). Targeting HSV-1 virionsfor specific binding to Epidermal Growth Factor Receptro-vIII on Tumor cells. MOLECULAR THERAPY, ISSN: 1525-0024Glorioso JC, GRANDI P., Krisky D, Goins W, Goss J, Fink DF (2006). HSV gene vectors and treatment of chronic painand cancer. JOURNAL OF NEUROIMMUNOLOGY, ISSN: 0165-5728GRANDI P., Fernandez J, Szentirmai O, Carter R, Breakefield XO (2006). Targeting HSV-1 Virions for Specific Bindingto Epidermal Growth Factor Receptor-VIII on Tumor Cells. MOLECULAR THERAPY, ISSN: 1525-0024BOZAC A, BERTO E, VASQUEZ F, GRANDI P., CAPUTO A, MANSERVIGI R, ENSOLI B, P. MARCONI (2006).Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector inducesantigen-specific T cell responses. VACCINE, vol. 24(49-50); p. 7148-7158, ISSN: 0264-410XGRANDI P. (2007). Design and application of HSV oncolytic vectors for treatment of brain tumors, Invited SpeakerConference: Oncolytic Viruses as Cancer Therapeutics. The 4th International Conference (Arizona-USA), March 14-17,2007GRANDI P., Forero A., Niranjan A, Fellows W, Okada H, Klinkenberg D, Krisky D, Glorioso J. (2007). Design of ICP0Deficient HSV Oncolytic Vectors for Treatment of Glioblastoma. MOLECULAR THERAPY, ISSN: 1525-0016GRANDI P., Forero A, Niranjan A. Fellows, W., Goins W., Okada, H., Klinkenberg, D, Krisky, D. and Glorioso, JC.(2007). Role of IDO on HSV oncolytic vectors activity. JOURNAL OF NEUROVIROLOGY, ISSN: 1355-0284GRANDI P. (2007). Novel Strategies for Enhancing Cancer Therapy using HSV Oncolytic Vectors. , Invited Speaker:The Clinical Oncology Grand Rounds, UPCIGRANDI P., Forero A, Niranjan Fellows W, Goins W, Okada H, Klinkenberg D, Krisky D, Glorioso JC (2007). Designof ICP0 Deficient Oncolytic HSV vectors for treatment of Glioblastoma. In: IHW (International Herpesvirus Workshop).Asheville, North Carolina (USA) , July 7-12, 2007GRANDI P. (2007). New Oncolytic HSV vectors for treatment of Glioblastoma. , Invited Speaker. 10th ASGT. May 30-June 3, 2007, Seattle, Washington, USA.GRANDI P. (2007). Novel Strategies for Enhancing Cancer Therapy Using HSV Oncolytic Vectors , Invited Speaker.Korea Institue of Radiological and Medical Sciences November 29, 2007, Seoul, South Korea7

GRANDI P. (2007). Role of IDO on HSV oncolytic vectors activity. , Invited Speaker. 8th International Symposium onNeuroVirology.San Diego October 29 th - November 2nd, 2007Forero A, Niranjan A, Fellows W, Okada H, Hiba C, Hong CS, Glorioso JC, GRANDI P. (2008). Effect of Indoleamine-2,3-Dioxygenase (IDO) on Replication of Oncolytic HSV Vectors in Glioma Cells. MOLECULAR THERAPY, ISSN:1525-0016GRANDI P. (2008). Effect of IDO on replication of oncolytic HSV vectors in glioma cells. , Invited Speaker: 9thInternational Congress of Neuroimmunology , Fort Worth, Texas 26-30 OctoberGRANDI P. (2008). Innate Immune Responses Limit HSV Oncolysis. , Invited Speaker. Gordon Conference, The Scienceof Viral Vector, March 2-7, 2008, Ventura, CaliforniaGRANDI P. (2008). Vector, March 2-7, 2008, Ventura, California Invited Speaker- Targeted delivery of glycine receptorsto peripheral neurons as treatment for pain , Universidad Montevideo-UruguayHong CH, Forero A, Niranjan A, Pollack I, GRANDI P. (2008). Methods to Enhance the Spread and Onclytic Activity ofHSV Vectors in GBM Therapy. . In: IHW . Estoril, Portugal, July 27 - August 1, 2008Marzulli M, Mazzacurati L, Uchida H, Justus Cohen, Reinhart B, Hong CH, Joseph Glorioso J, GRANDI P. (2010).Design and application of a new HSV vector for treatment of Glioblastoma. In: European Society Gene and cell therapyMarzulli M, Mazzacurati L, Uchida H, Cohen J, Reinhart B, Hong CH, Glorioso J, GRANDI P. (2010). AdvancedOncolity vectors for treatment of brain tumors. JOURNAL OF NEUROVIROLOGY, ISSN: 1355-0284GRANDI P. (2011). MicroRNA control of HSV-1 replication for the treatment of glioblastoma multiforme. , InvitedSpeaker. IHW 2011, July 24-28, Gdansk, PollandMazzacurati L, Marzulli M, Reinhart B, Cohen J, GLorioso J, GRANDI P. (2011). MicroRNA control of HSV-1replication for the treatment of glioblastoma multiforme. In: IHW 2011 Gdansk, PollandGRANDI P. (2011). Targeting oncolytic HSV replication to brain tumors. . In: Oncolytic viruses as a cancer therapeutics.March 16-19, 2011, Las Vegas, NVGRANDI P., GLorioso J (2011). Glioblastoma restricted oHSV replication based on vector retargeting and microRNAcontrol of essential virus gene expression. In: 15th International Conference on Immunobiology and Prophylaxis ofHuman Herpesvirus Infections. venice, October 13-15, 2011.Mazzacurati L, Marzulli M, Reinhart B, Cohen J, Glorioso JC, GRANDI P. (2011). MicroRNA Control of HSV-1Replication for the Treatment of Glioblastoma Multiforme. MOLECULAR THERAPY, ISSN: 1525-0024GRANDI P. (2011). Targeting oncolytic HSV replication to brain tumors. , Invited Speaker. Oncolytic viruses as a cancertherapeutics. March 16-19, 2011, Las Vegas, NVGRANDI P. (2011). HSV-1 based controlled oncolytic vector for the treatment of glioblastoma multiforme.ASCGT, May19-23, 2011 Seattle, WAMarzulli M, Mazzacurati L, Reinhart B, Glorioso JC, Cohen J, GRANDI P. (2012). A New Class of GlioblastomaRestricted oHSV Replication Based on microRNA Control of Essential Virus Gene Expression. MOLECULARTHERAPY, ISSN: 1525-0016Uchida H, Marzulli M, Chan J, Mazzacurati M, Goins W, Zhang M, Hong C-S, Nakashima H, Haseley A, Yoo J-Y, KaurB, Chiocca A, GRANDI P., Cohen J, Glorioso JC (2012). Efficient HSV-1 Retargeting by Modification of GlycoproteinsD and B. MOLECULAR THERAPY, ISSN: 1525-00248

Miyagawa Y, Cohen J, Simonato M, GRANDI P., Glorioso JC (2012). DEVELOPMENT OF AN EFFICIENT ANDVERSATILE HERPES SIMPLEX VIRUS VECTOR SYSTEM FOR CELLULAR REPROGRAMMING. In:International Society for Stem Cell Research, 10th annual meeting . yokohama Japan , june 13-16, 2012GRANDI P. (2012). Efficient HSV-1 Retargeting by Modification of Glycoproteins D and B , Oral presentation. ASGCT15th Annual Meeting, May 16-19, 2012 in Philadelphia, PA, USAGRANDI P. (2012). Development of a new class of tumor targeted oncolytic HSV vectors, Invited Speaker. September 19- 22, 2012. Orvieto9